Related Experiment Video

Updated: Mar 29, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Association between ADAM33 S2 and V4 polymorphisms and susceptibility to allergic rhinitis: A meta-analysis

Zewen Li1, Fubo Yan1, Zhimin Yang2

  • 1Department of Otolaryngology, The Central Hospital of Xiaogan, Tongji Medical College, Huazhong University of Science Technology, Xiaogan, Hubei, China.

Allergologia Et Immunopathologia
|December 2, 2015
PubMed
Abstract

Insights

Genetic variations in ADAM33 (a disintegrin and metalloproteinase domain 33) are linked to allergic rhinitis (AR) susceptibility. Specifically, ADAM33 S2 and V4 polymorphisms increase the risk of developing AR, though further research is needed.

Area of Science:

  • Genetics
  • Immunology
  • Allergy Research

Background:

  • ADAM33 (a disintegrin and metalloproteinase domain 33) gene polymorphisms have been suggested as potential risk factors for allergic rhinitis (AR).
  • Previous studies on the association between ADAM33 polymorphisms and AR susceptibility have yielded inconsistent results.

Purpose of the Study:

  • To conduct a systematic meta-analysis to clarify the association between specific ADAM33 polymorphisms (S2, V4, T1, T2, T+1) and the risk of allergic rhinitis.
  • To consolidate existing evidence and provide a more definitive conclusion on the genetic contribution of ADAM33 to AR.

Main Methods:

  • A comprehensive literature search was performed in PubMed and Embase to identify relevant case-control studies.
  • Five case-control studies, involving 1251 patients with AR and 1634 controls, were included in the meta-analysis.
  • Statistical analysis was conducted using various genetic comparison models (allele, heterozygote, dominant).

Main Results:

  • The meta-analysis found a significant association between ADAM33 S2 polymorphism and increased AR susceptibility across allele, heterozygote, and dominant genetic models.
  • ADAM33 V4 polymorphism also showed a significant association with AR risk in the allele comparison.
  • No significant association was observed between ADAM33 T1, T2, and T+1 polymorphisms and AR risk in any genetic model.

Conclusions:

  • The ADAM33 S2 and V4 polymorphisms are associated with an increased susceptibility to allergic rhinitis.
  • The findings should be interpreted cautiously due to limitations in sample size and study heterogeneity.
  • Larger, well-designed studies are recommended to validate these findings and further elucidate the role of ADAM33 in AR.
Keywords:
ADAM33Allergic rhinitisMeta-analysisPolymorphismsSusceptibility

More Related Videos

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.8K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Allergic Reactions02:06

Allergic Reactions

Overview
33.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
172
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.6K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K